Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study

References

• Mocsai A, Kovacs L, Gergely P. What is the future of targeted therapy in rheumatology: biologics or small molecules? BMC Med. 2014;12(1):43. doi: 10.1186/1741-7015-12-43
   PubMedGoogle Scholar
• Sandborn WJ, Su C, Sands BE, et al. OCTAVE induction 1, OCTAVE induction 2, and OCTAVE sustain investigators. tofacitinib as induction and maintenance therapy for ulcerative colitis. New Engl J Med. 2017;376(18):1723–1736. doi: 10.1056/NEJMoa1606910
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Lawendy N, Danese S. Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE open, an open-label, long-term extension study with up to 7.0 years of treatment. Aliment Pharmacol Ther. 2022;55(4):464–478. doi: 10.1111/apt.16712
   PubMed Web of Science ®Google Scholar
• Weisshof R, Aharoni Golan M, Sossenheimer PH, et al. Real-world experience with tofacitinib in IBD at a tertiary center. Dig Dis Sci. 2019;64(7):1945–1951. doi: 10.1007/s10620-019-05492-y
   PubMed Web of Science ®Google Scholar
• Honap S, Chee D, Chapman TP, et al. LEO [London, Exeter, Oxford] IBD research consortium. real world effectiveness of tofacitinib for moderate to severe ulcerative colitis: a multicentre UK experience. J Crohns Colitis. 2020;14(10):1385–1393. doi: 10.1093/ecco-jcc/jjaa075
   PubMed Web of Science ®Google Scholar
• Biemans VBC, de Vries AC SJ, de Vries AC, et al. Dutch initiative on Crohn and colitis (ICC).Tofacitinib for ulcerative colitis: results of the prospective Dutch initiative on Crohn and colitis (ICC) registry. Aliment Pharmacol Ther. 2020;51(9):880–888. doi: 10.1111/apt.15689
   PubMed Web of Science ®Google Scholar
• Lair-Mehiri L, Stefanescu C, Vaysse T, et al. Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis. Dig Liver Dis. 2020;52(3):268–273. doi: 10.1016/j.dld.2019.10.003
   PubMedGoogle Scholar
• Chaparro M, Garre A, Mesonero F, et al. Tofacitinib in ulcerative colitis: real world evidence from the ENEIDA registry. J Crohn’s Colitis. 2021;15(1):35–42. doi: 10.1093/ecco-jcc/jjaa145
   Google Scholar
• Deepak P, Alayo QA, Khatiwada A, et al. Safety of tofacitinib in a real world cohort of patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2021;19(8):1592–1601. doi: 10.1016/j.cgh.2020.06.050
   PubMed Web of Science ®Google Scholar
• Raine T, Bonovas S, Burish J, et al. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis. 2022;16(1):2–17. doi: 10.1093/ecco-jcc/jjab178
   PubMed Web of Science ®Google Scholar
• Avni-Biron I, Bar-Gil Shitrit A, Koslowsky B, et al. Short-term effectiveness and safety of tofacitinib in ulcerative colitis - real world data from tertiary medical centers in israel. Dig Liver Dis. 2022;54(2):192–197. doi: 10.1016/j.dld.2021.11.009
   PubMedGoogle Scholar
• Nakamura M, Yamamura T, Maeda K, et al. Initial experience of tofacitinib for treating refractory moderate-to-severe ulcerative colitis. Nagoya J Med Sci. 2022;84(1):169–179 82022. doi: 10.18999/nagjms.84.1.169
   PubMed Web of Science ®Google Scholar
• Straatmijer T, van Schaik FDM, Bodelier AGL, et al. Initiative on Crohn and colitis. Effectiveness and safety of tofacitinib for ulcerative colitis: two-year results of the ICC registry. Aliment Pharmacol Ther. 2023;57(1):117–126. doi: 10.1111/apt.17248
   PubMed Web of Science ®Google Scholar
• Long MD, Afzali A, Fischer M, et al. Tofacitinib response in ulcerative colitis (TOUR): early response after initiation of tofacitinib therapy in a real-world setting. Inflamm Bowel Dis. 2023;3(4):570–578. doi: 10.1093/ibd/izac121
   Google Scholar
• Parra-Izquierdo V, Frías-Ordoñez JS, Márquez JR, et al. Tofacitinib in the treatment of moderate to severe ulcerative colitis in Colombia: real world experience. Gastroenterol Hepatol. 2022 Nov 11;S0210-5705(22). doi: 10.1016/j.gastrohep.2022.10.02000266-7
   Google Scholar
• Regime di rimborsabilità e prezzo, a seguito di nuove indicazioni terapeutiche, del medicinale per uso umano “Xeljanz”. GAZZETTA UFFICIALE DELLA REPUBBLICA ITALIANA del 17.12.2020; Serie generale n. 312: p. 24–29.
   Google Scholar
• Magro F, Gionchetti P, Eliakim R, et al. European Crohn’s and Colitis Organisation [ECCO]. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, Diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis. 2017;11(6):649–670. doi: 10.1093/ecco-jcc/jjx008
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Loftus EV, Isaacs KL, et al. ACG clinical guideline: management of crohn’s disease in adults. Am J Gastroenterol. 2018;113(4):481–517. doi: 10.1038/ajg.2018.27
   PubMed Web of Science ®Google Scholar
• Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55(6):749–753. doi: 10.1136/gut.2005.082909
   PubMed Web of Science ®Google Scholar
• Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. N Eng J Med. 1987;317(26):1625–1629. doi: 10.1056/NEJM198712243172603
   PubMed Web of Science ®Google Scholar
• SONIC Study Group, Colombel JF, Sandborn WJ, Reinisch W, et al Infliximab, azathioprine, or combination therapy for crohn’s disease. N Engl J Med. 2010;362(15):1383–1395.
   PubMed Web of Science ®Google Scholar
• Lucaciu LA, Constantine-Cooke N, Plevris N, et al. Real-world experience with tofacitinib in ulcerative colitis: a systematic review and meta-analysis. Therap Adv Gastroenterol. 2021;14:17562848211064004. doi: 10.1177/17562848211064004
   Web of Science ®Google Scholar
• Charles-Schoeman C, Gonzalez-Gay MA, Kaplan I, et al. Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist. Semin Arthritis Rheum. 2016;46(1):71–80. doi: 10.1016/j.semarthrit.2016.03.004
   PubMed Web of Science ®Google Scholar
• Alves C, Penedones A, Mendes D, Marques FB. Risk of cardiovascular and venous thromboembolic events associated with janus kinase inhibitors in rheumatoid arthritis: a systematic review and network meta-analysis. J Clin Rheumatol. 2022;28(2):69–76. doi: 10.1097/RHU.0000000000001804
   PubMed Web of Science ®Google Scholar
• Mease P, Charles-Schoeman C, Cohen S, et al. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data. Ann Rheum Dis. 2020;79(11):1400–1413. doi: 10.1136/annrheumdis-2019-216761
   PubMed Web of Science ®Google Scholar
• Papa A, Tursi A, Danese S, et al. Venous thromboembolism in patients with inflammatory bowel disease: the role of pharmacological therapy and surgery. J Clin Med. 2020;9(7):2115–82020. doi: 10.3390/jcm9072115
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Vermeire S, Long MD, et al. Long-term risk of herpes zoster infection in patients with ulcerative colitis receiving tofacitinib. Inflamm Bowel Dis. 2023;29(1):85–96 82023. doi: 10.1093/ibd/izac063
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Bressler B, Francisconi C, et al. Assessment of safety and efficacy of tofacitinib, stratified by age, in patients from the ulcerative colitis clinical program. Inflamm Bowel Dis. 2023;29(1):27–41. doi: 10.1093/ibd/izac084
   PubMed Web of Science ®Google Scholar